A semi-synthetic method for preparing methylkynurenine daptomycin
By using a one-pot reductive amination reaction, daptomycin is converted into methylkynurenine daptomycin, which solves the problems of low efficiency and high cost of the existing total synthesis process of Kynomycin. This achieves highly selective and low-cost semi-synthetic preparation, which is suitable for industrial applications.
Patent Information
- Application Number
- CN202611321572.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-28
- Publication Date
- 2026-11-17
AI Technical Summary
The existing total synthesis process of Kynomycin is cumbersome, has low yield, high cost, and is difficult to industrialize, while there is a lack of semi-synthetic modification technology solutions.
A one-pot reductive amination reaction is adopted, using formaldehyde and sodium cyanoborohydride or 2-methylpyridineborane as reducing agents to convert daptomycin to methylkynurenine daptomycin under acidic conditions, simplifying the reaction to a single step and avoiding complex steps and high costs.
This method enables highly selective and low-cost preparation of Kynomycin, significantly improving product purity and yield, making it suitable for industrial production, and reducing production cycle and equipment requirements.
Smart Images

Figure CN123106834A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a semi-synthetic method for preparing methylkynurenine daptomycin, belonging to the field of cyclic lipopeptide antibacterial drug synthesis technology. Background Technology
[0002] Kynomycin (methylkynurenine daptomycin) is a novel cyclic lipopeptide antibacterial compound currently in Phase II clinical trials in China. This class of compounds exhibits excellent antibacterial activity against multidrug-resistant Gram-positive bacteria (including MRSA, VRE, and other drug-resistant pathogens), and is primarily indicated for bacterial skin diseases caused by Gram-positive bacterial infections. Compared to the already marketed daptomycin, Kynomycin has a higher resistance barrier and better antibacterial stability, thus being considered a highly promising candidate molecule for novel anti-infective drugs.
[0003] In existing technologies, the preparation of Kynomycin mainly relies on total synthesis. Specifically, the reported technical routes typically use amino acid monomers as starting materials, assembling linear peptide chains stepwise through solid-phase peptide synthesis, followed by resin cleavage, macrocyclization in solution, and chemical modification of specific sites to finally obtain the target product. However, this type of total synthesis route has several inherent drawbacks. First, due to the multiple steps of amino and carboxyl group protection and deprotection operations involved in the synthesis, the overall reaction steps are lengthy and the process is complex and cumbersome. Second, single-batch synthesis usually takes several days, resulting in a long reaction cycle and low synthesis efficiency. Furthermore, the accumulation of a large number of byproducts in multiple steps leads to poor reaction selectivity, resulting in an overall synthesis yield that is usually less than 5%. In addition, this route requires harsh reaction conditions and expensive reagents, resulting in extremely high preparation costs, making it difficult to meet the economic and efficiency requirements for industrial-scale production. These shortcomings seriously restrict the new drug development process of Kynomycin and its clinical translation application.
[0004] Currently, there are no reports in existing technologies regarding the semi-synthetic preparation of Kynomycin from industrially produced daptomycin. Daptomycin, as a mature cyclic lipopeptide raw material already produced on a large industrial scale, has the advantages of low cost, stable market supply, and easy availability. Theoretically, if efficient conversion to Kynomycin can be achieved through site-selective chemical modification based on the molecular skeleton of daptomycin, it is hoped that the lengthy route of traditional total synthesis can be avoided. However, how to establish a mild, simple, and efficient semi-synthetic process to achieve this selective modification conversion remains a challenge.
[0005] In view of the shortcomings of existing total synthesis processes, such as low efficiency, high cost and poor industrial feasibility, as well as the technological gap in the field of semi-synthetic modification, there is an urgent need in this field to develop a synthetic method that can efficiently prepare Kynomycin from daptomycin under mild conditions through simplified operation, thereby providing a process foundation for the large-scale preparation and subsequent development and application of Kynomycin. Summary of the Invention
[0006] This invention addresses the shortcomings of existing total synthesis processes for Kynomycin, such as cumbersome steps, low yield, high cost, and difficulty in industrialization, by providing a semi-synthetic method for preparing methylkynurinine daptomycin.
[0007] The technical solution of the present invention to solve the above-mentioned technical problems is as follows: A semi-synthetic method for preparing methylkynurenine daptomycin includes the following steps: Daptomycin was dissolved in a solvent, the system was adjusted to acidity, formaldehyde and a reducing agent were added, and a one-pot reductive amination reaction was carried out to prepare methylkynurenine daptomycin.
[0008] Furthermore, the solvent is water, and the molar ratio of daptomycin to water is 1:5000-6000.
[0009] Furthermore, the reducing agent is selected from sodium cyanoborohydride or 2-methylpyridineborane.
[0010] Furthermore, the system is adjusted to acidity using formic acid or glacial acetic acid, so that the pH value of the system meets the following condition: 3.0 < pH value ≤ 4.0.
[0011] Furthermore, the molar ratio of daptomycin to formaldehyde is 1:1.0 to 1:1.1.
[0012] Furthermore, the molar ratio of daptomycin to reducing agent is 1:2.0.
[0013] Furthermore, the reaction temperature is 20℃~25℃, and the reaction time is 10 minutes~15 minutes.
[0014] Furthermore, it also includes a post-processing step: after the reaction is complete, the reaction system is extracted with an organic solvent and the aqueous layer is collected.
[0015] Furthermore, the organic solvent in the post-processing step is dichloromethane.
[0016] Furthermore, it also includes a purification step: purifying the collected aqueous layer using high-performance liquid chromatography and collecting the target product fraction.
[0017] Compared with the prior art, the present invention has the following beneficial effects: This invention achieves highly selective N-methylation of the kynurenine site in daptomycin by controlling the acidity of the reaction system with a weak acid and combining it with a formaldehyde-sodium cyanoborohydride reduction amination system. This effectively inhibits the formation of polymethylation byproducts, while other sensitive amino and hydroxyl groups in the molecule remain unaffected. The purity and yield of the product are significantly better than those of traditional processes.
[0018] This invention abandons the existing total synthetic route involving amino acid assembly and cyclization, and provides a method for the semi-synthetic preparation of methylkynurenine daptomycin using industrially produced daptomycin as a raw material. It eliminates the need for complex steps such as peptide synthesis, protection and deprotection, and macrocyclic cyclization, simplifying the process from the synthetic origin and reducing multiple reaction steps to a single step, significantly shortening the production cycle. This invention employs a one-pot reaction, with all reagents added at once, eliminating the need for complex operations such as intermediate separation and anhydrous / oxygen-free processes. The process is extremely simple and has low equipment requirements.
[0019] The reaction conditions of this invention are mild and can be completed under normal temperature, normal pressure, and aqueous phase conditions. It has low energy consumption, high safety, and is environmentally friendly.
[0020] The raw materials of this invention are readily available, the reagents are inexpensive, the process is simple, and there are few by-products, resulting in a significant reduction in overall production costs. The total yield is much higher than that of traditional total synthesis processes, and the purity of the product can reach over 96%. This provides a high-quality, low-cost raw material guarantee for the drug development and clinical application of Kynomycin, and has extremely high industrial application value. Attached Figure Description
[0021] Figure 1 This is the high-performance liquid chromatography purity analysis chromatogram of the product obtained in Example 1 of the present invention before purification; Figure 2 The high-performance liquid chromatography (HPLC) purity analysis chromatogram of the product prepared in Comparative Example 1 of this invention. Figure 3 The high-performance liquid chromatography purity analysis chromatogram of the product obtained in Comparative Example 2 of this invention; Figure 4 The high-performance liquid chromatography purity analysis chromatogram of the product obtained in Comparative Example 6 of this invention; Figure 5 The high-performance liquid chromatography purity analysis chromatogram of the product obtained in Comparative Example 3 of this invention; Figure 6 The high-performance liquid chromatography purity analysis chromatogram of the product obtained in Comparative Example 4 of this invention. Figure 7 The high-performance liquid chromatography purity analysis chromatogram of the product obtained in Comparative Example 5 of this invention. Figure 8 This is the high-performance liquid chromatography purity analysis chromatogram of the product obtained in Example 2 of the present invention before extraction; Figure 9This is the high-performance liquid chromatography purity analysis chromatogram of the product obtained in Example 2 of the present invention after extraction; Figure 10 This is a high-performance liquid chromatography purity analysis chromatogram of the purified product obtained in Example 1 of the present invention; Figure 11 The high-resolution mass spectrometry (HRMS) spectrum of Kynomycin obtained in Example 1 of this invention; Figure 12 The proton nuclear magnetic resonance spectrum of Kynomycin prepared in Example 1 of this invention ( 1 H NMR spectrum; Figure 13 The carbon NMR spectrum of Kynomycin prepared in Example 1 of this invention ( 13 C NMR spectrum. Detailed Implementation
[0022] The principles and features of the present invention are described below with reference to the accompanying drawings. The examples given are only for explaining the present invention and are not intended to limit the scope of the present invention.
[0023] The daptomycin raw material used in the various embodiments of the present invention can be commercially available industrial-grade daptomycin or daptomycin obtained through fermentation purification.
[0024] The reaction conversion rate and product purity were determined by high-performance liquid chromatography (HPLC). HPLC conditions were as follows: a C18 column, a mobile phase of water-acetonitrile-0.1% trifluoroacetic acid, elution process: 2%-90% (B) for 20 min, and a detection wavelength of 254 nm. The structure of the product was confirmed by nuclear magnetic resonance spectroscopy and high-resolution mass spectrometry.
[0025] Example 1 A method for the semi-synthetic preparation of Kynomycin using daptomycin as a starting material, comprising the following steps: (1) Dissolution: Take 0.03 mmol daptomycin, add 2.9 mL pure water, and stir at room temperature (25℃) until completely dissolved; (2) Adjusting pH: Add glacial acetic acid dropwise to adjust the pH of the system to 4.0; (3) Reaction: 0.03 mmol formaldehyde and 0.06 mmol sodium cyanoborohydride were added sequentially, and the mixture was stirred at room temperature for 10 min. (4) Purification: After the reaction was completed, the aqueous solution was purified by high performance liquid chromatography. The mobile phase was water-acetonitrile-0.1% trifluoroacetic acid system. The target product peak fraction was collected and freeze-dried to obtain yellow powder Kynomycin.
[0026] Please refer to the HPLC chromatogram of the product before purification in this embodiment. Figure 1 , where tR The peak at 14.0 min is the peak of the raw material daptomycin. R The peak at 14.4 min is the peak of the target product kynomycin. The HPLC chromatogram of the purified product in this example can be found in [reference needed]. Figure 10 See high-resolution mass spectrum. Figure 11 See the hydrogen NMR spectrum. Figure 12 See the carbon NMR spectrum of Kynomycin. Figure 13 Testing showed that the conversion rate of this embodiment was 94.0%, the purity of the target product after purification was ≥96%, and the total synthesis yield reached 52.0%, which is much higher than the yield of traditional total synthesis processes.
[0027] Molecular formula structure of Kynomycin: .
[0028] Kynomycin's characterization data: 1 H NMR (600 MHz, DMSO- d 6 with D2O) δ 7.81 (d, J = 8.2 Hz, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.38 (t, J = 7.2 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.14 (s,1H), 7.04 (t, J = 8.0 Hz, 1H), 6.95 (t, J = 8.5 Hz, 1H), 6.70 (d, J = 8.7 Hz, 1H), 6.58 (t, J = 7.5 Hz, 1H), 5.14 – 5.09 (m, 1H), 4.84 – 4.80 (m, 1H), 4.64 – 4.58 (m, 2H), 4.56 – 4.51 (m, 2H), 4.51 – 4.46 (m, 2H), 4.45 (t, J = 5.7 Hz, 1H), 4.33 (dd, J = 9.0, 5.4 Hz, 1H), 4.21 – 4.16 (m, 2H), 3.90 – 3.71 (m, 3H), 3.65 – 3.54 (m, 4H), 3.01 (dd, J= 14.6, 5.1 Hz, 1H), 2.93 – 2.86 (m, 2H),2.85 – 2.83 (m, 1H), 2.81 (s, 4H), 2.76 – 2.71 (m, 1H), 2.58 – 2.55 (m, 2H),2.54 – 2.53 (m, 1H), 2.47 – 2.45 (m, 1H), 2.43 – 2.39 (m, 1H), 2.35 – 2.30(m, 2H), 2.27 – 2.16 (m, 1H), 2.04 – 1.99 (m, 2H), 1.94 – 1.87 (m, 1H), 1.80– 1.74 (m, 1H), 1.73 – 1.66 (m, 1H), 1.65 – 1.57 (m, 2H), 1.38 – 1.32 (m,2H), 1.25 – 1.21 (m, 3H), 1.21 – 1.16 (m, 7H), 1.15 – 1.11 (m, 4H), 1.10 –1.04 (m, 5H), 0.85 – 0.80 (m, 6H). 13 C NMR (151 MHz, DMSO- d6with D2O) δ 173.70, 173.33, 173.15, 172.17,172.10, 171.65, 171.60, 171.12, 170.67, 170.60, 170.51, 170.40, 170.26,170.17, 170.09, 169.35, 169.00, 158.41, 158.19, 151.37, 136.07, 132.18,127.33, 123.76, 121.08, 118.49, 118.41, 116.45, 114.28, 111.43, 109.87, 70.42, 62.02, 55.41, 55.02, 54.45, 52.64, 52.58, 50.14, 50.00, 49.86, 49.57, 48.93, 48.28, 48.18, 45.94, 42.28, 42.09, 38.64, 38.55, 38.10, 36.98, 35.82, 35.64, 35.14, 35.10, 33.40, 31.43, 29.15, 29.00, 28.90, 28.84, 28.73, 28.36, 27.11, 25.11, 23.44, 23.39, 22.27, 17.67, 15.34, 14.74, 14.15. Example 2 A method for the semi-synthetic preparation of Kynomycin using daptomycin as a starting material, comprising the following steps: (1) Dissolution: Take 0.01 mmol of daptomycin, add 1 mL of pure water, and stir at room temperature for 0.5 min to dissolve; (2) Adjusting pH: Add glacial acetic acid dropwise to adjust the pH of the system to 4.0; (3) Reaction: 0.01 mmol of formaldehyde and 0.02 mmol of 2-methylpyridineborane were added sequentially, and the mixture was stirred at room temperature for 15 min. (4) Post-treatment: Extracted three times with dichloromethane, the aqueous layer was collected, and the dichloromethane was evaporated under reduced pressure.
[0029] (5) The aqueous solution was purified by high performance liquid chromatography. The mobile phase was water-acetonitrile-0.1% trifluoroacetic acid system. The target product peak fraction was collected and freeze-dried to obtain yellow powder Kynomycin.
[0030] Please refer to the HPLC chromatograms of the products before and after extraction in this embodiment. Figures 8-9As can be seen, dichloromethane extraction effectively removes lipid-soluble impurities, improving the purity of the target product Kynomycin in the aqueous layer. The conversion rate in this example was measured to be 97.2%. The results indicate that using 2-methylpyridineborane as an alternative reducing agent can achieve efficient and highly selective N-methylation conversion at pH 4.0.
[0031] Using 2-methylpyridineborane as a reducing agent has the advantages of lower cost and better environmental friendliness. It does not produce toxic byproducts such as hydrogen cyanide during the reaction process, making it suitable for industrial-scale production.
[0032] Comparative Example 1 A method for the semi-synthetic preparation of Kynomycin using daptomycin as a starting material, comprising the following steps: (1) Dissolution: Take 0.01 mmol of daptomycin, add 1 mL of pure water, and stir to dissolve at room temperature; (2) Reaction: 0.012 mmol formaldehyde and 0.02 mmol sodium cyanoborohydride were added sequentially, and the mixture was stirred at room temperature for 4 h.
[0033] Please refer to the HPLC chromatogram of the comparative product. Figure 2 The conversion rate of this comparative sample was 42.1%, indicating an incomplete reaction.
[0034] Compared with Example 1, this comparative example did not perform acid adjustment before the reaction, resulting in a higher pH value in the system, which is not conducive to the efficient conduct of the reductive amination reaction, thus causing low conversion rate and excessively long reaction time.
[0035] Comparative Example 2 A method for the semi-synthetic preparation of Kynomycin using daptomycin as a starting material, comprising the following steps: (1) Dissolution: Take 0.01 mmol of daptomycin, add 1 mL of pure water, and stir at room temperature for 0.5 min to dissolve; (2) Adjusting pH: Add glacial acetic acid dropwise to adjust the pH of the system to 3.0; (3) Reaction: 0.012 mmol formaldehyde and 0.02 mmol sodium cyanoborohydride were added sequentially, and the mixture was stirred at room temperature for 10 min.
[0036] Please refer to the HPLC chromatogram of the comparative product. Figure 3 The conversion rate of this comparative sample was 98.6%, but it was accompanied by the generation of a large number of byproducts.
[0037] The reaction system of this comparative example is more acidic than that of Example 1. Although the conversion rate is improved, the stronger acidity leads to over-reaction and increased by-products. In addition, the excess formaldehyde in this comparative example is also a reason for the increase in by-products.
[0038] Comparative Example 3 A method for the semi-synthetic preparation of Kynomycin using daptomycin as a starting material, comprising the following steps: (1) Dissolution: Take 0.01 mmol of daptomycin, add 1 mL of pure water, and stir at room temperature for 0.5 min to dissolve; (2) Adjusting pH: Add glacial acetic acid dropwise to adjust the pH of the system to 3.0; (3) Reaction: 0.02 mmol formaldehyde and 0.02 mmol sodium cyanoborohydride were added sequentially, and the mixture was stirred at room temperature for 5 min.
[0039] Please refer to the HPLC chromatogram of the comparative product. Figure 5 Testing revealed that the conversion rate of this comparative example was 100.0%, but it was accompanied by the generation of a large number of byproducts.
[0040] The reaction system in this comparative example is more acidic than that in Example 1. Although the conversion rate is improved, the stronger acidity leads to excessive reaction and the amount of formaldehyde used is seriously excessive, resulting in a large number of byproducts.
[0041] Comparative Example 4 A method for the semi-synthetic preparation of Kynomycin using daptomycin as a starting material, comprising the following steps: (1) Dissolution: Take 0.01 mmol of daptomycin, add 1 mL of pure water, and stir at room temperature for 0.5 min to dissolve; (2) Acid adjustment: Add formic acid dropwise to adjust the pH of the system to 1.0; (3) Reaction: 0.01 mmol formaldehyde and 0.02 mmol sodium cyanoborohydride were added sequentially, and the mixture was stirred at room temperature for 5 min.
[0042] Please refer to the HPLC chromatogram of the comparative product. Figure 6 The conversion rate of this comparative example was 100.0%, but it was accompanied by the generation of a large number of byproducts.
[0043] The reaction system in this comparative example exhibited significantly enhanced acidity (pH=1.0). Although complete conversion of daptomycin was achieved, the strongly acidic environment led to the generation of a large number of byproducts. Therefore, despite the accelerated reaction rate and improved conversion rate under these conditions, the amount of the target product was relatively small, which is not conducive to large-scale production.
[0044] Comparative Example 5 A method for the semi-synthetic preparation of Kynomycin using daptomycin as a starting material, comprising the following steps: (1) Dissolution: Take 0.01 mmol of daptomycin, add 1 mL of pure water, and stir at room temperature for 0.5 min to dissolve; (2) Adjusting pH: Add glacial acetic acid dropwise to adjust the pH of the system to 3.0; (3) Reaction: 0.01 mmol formaldehyde and 0.02 mmol sodium borohydride acetate were added sequentially, and the mixture was stirred at room temperature for 2 h.
[0045] Please refer to the HPLC chromatogram of the comparative product. Figure 7 The conversion rate of this comparative example was 39.5%, indicating that the reaction of the raw materials was incomplete.
[0046] In this comparative example, sodium borohydride acetate was used as a reducing agent. Compared with sodium cyanoborohydride used in Example 1, sodium borohydride acetate has a weaker reducing ability and cannot achieve effective conversion of daptomycin.
[0047] Comparative Example 6 A method for the semi-synthetic preparation of Kynomycin using daptomycin as a starting material, comprising the following steps: (1) Dissolution: Take 0.01 mmol of daptomycin, add 1 mL of pure water, and stir at room temperature for 0.5 min to dissolve; (2) Adjusting pH: Add glacial acetic acid dropwise to adjust the pH of the system to 3.0; (3) Reaction: 0.01 mmol formaldehyde and 0.02 mmol sodium cyanoborohydride were added sequentially, and the mixture was stirred at room temperature for 15 min. Please refer to the HPLC chromatogram of the comparative product. Figure 4 The conversion rate of this comparative sample was 91.8%, with the production of byproducts.
[0048] The reaction system in this comparative example is more acidic than that in Example 1. Although the conversion rate is improved, the stronger acidity leads to over-reaction and an increase in the production of by-products.
[0049] This invention establishes for the first time a novel semi-synthetic process for the one-pot reductive amination of daptomycin at room temperature, using acetic acid to regulate acidity and a formaldehyde-sodium cyanoborohydride or formaldehyde-2-methylpyridineborane system to synthesize Kynomycin. This process overcomes the technical barriers of traditional total synthesis. The process boasts advantages such as simple steps, mild conditions, high selectivity, excellent yield, and low cost, enabling the efficient and large-scale preparation of Kynomycin and providing core technical support for the industrial-scale research and development of novel antibacterial drugs for drug-resistant bacteria.
[0050] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A method for the semi-synthetic preparation of methylkynurenine daptomycin, characterized in that, Includes the following steps: Daptomycin was dissolved in a solvent, the system was adjusted to acidity, formaldehyde and a reducing agent were added, and a one-pot reductive amination reaction was carried out to prepare methylkynurenine daptomycin.
2. The method for semi-synthetically preparing methylkynurenine daptomycin according to claim 1, characterized in that, The solvent is water.
3. The method for semi-synthetically preparing methylkynurenine daptomycin according to claim 1, characterized in that, The reducing agent is selected from sodium cyanoborohydride or 2-methylpyridineborane.
4. The method for semi-synthetically preparing methylkynurenine daptomycin according to claim 1, characterized in that, The system is adjusted to acidity using formic acid or glacial acetic acid, so that the pH value of the system meets the following condition: 3.0 < pH value ≤ 4.
0.
5. The method for semi-synthetically preparing methylkynurenine daptomycin according to claim 1, characterized in that, The molar ratio of daptomycin to formaldehyde is 1:1.0 to 1:1.
1.
6. The method for semi-synthetically preparing methylkynurenine daptomycin according to claim 1, characterized in that, The molar ratio of daptomycin to reducing agent is 1:2.
0.
7. The method for semi-synthetically preparing methylkynurenine daptomycin according to claim 1, characterized in that, The reaction temperature is 20℃~25℃, and the reaction time is 10 minutes~15 minutes.
8. The method for semi-synthetically preparing methylkynurenine daptomycin according to any one of claims 1 to 7, characterized in that, It also includes a post-processing step: after the reaction is complete, the reaction system is extracted with an organic solvent and the aqueous layer is collected.
9. The method for semi-synthetically preparing methylkynurenine daptomycin according to claim 8, characterized in that, The organic solvent used in the post-processing step is dichloromethane.
10. The method for semi-synthetically preparing methylkynurenine daptomycin according to claim 9, characterized in that, It also includes a purification step: the collected aqueous layer is purified by high performance liquid chromatography, and the target product fraction is collected.
